WS16.01 Highly-effective CFTR modulator therapy with elexacaftor/tezacaftor/ivacftor (ETI) leads to age-dependent changes of typical cystic fibrosis hallmark pathogens – data from the German cystic fibrosis registry

Abstract

Objectives: The impressive improvements of CFTR function by elexacaftor/tezacaftor/ivacaftor (ETI) result in remarkable changes of pulmonary function and structural lung disease. Whether these effects translate to changes of microbial patterns, an equally critical aspect of CF lung disease, remains to be shown. To examine the effect of ETI on Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) detections in people with CF (pwCF) ≥12 years.